Anna Sureda's guest appearances

Anna Sureda

The Onco'Zine Brief

The Graft 

Chris Lewis

Charlie Johnson

Vincent Rajkumar

Noopur Raje

Otis Brawley

Armon Sharei

Neil Canavan

Richard Schilsky

Susan Rafte

Catherine Ivy

Manon Rinsma

Phil Rowlands

Chadi Nabhan

Aaron Goodman

Valena Wright

OwlTail

#16 Anna Sureda: EBMT - present, future

In this edition of The Onco'Zine Brief, recorded during the 59th annual meeting of the American Society of Hematology - held December 9 to 12, 2017 in Atlanta, Georgia (USA), we talk with Anna Sureda, MD, Ph.D, Head of the Hematology Department at the Catalan Institute of Oncology, Barcelona, Spain - to discuss some of the exciting developments in the treatment of patients with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and Multiple Myeloma. During our conversation we asked Dr Sureda about what she thinks about the exciting treatment options presented at the 59th Annual Meeting of the American Society of Hematology as well as the differences in how patients are being treated in the United States vs. Spain. And we asked Dr Sureda about a particular study, the ECHELON-1, about the reason for the study, the study outcomes and what the results of this study mean for patients with advanced frontline Hodgkin lymphoma.

In this edition of The Onco'Zine Brief, recorded during the 59th annual meeting of the American Society of Hematology - held December 9 to 12, 2017 in Atlanta, Georgia (USA), we talk with Anna Sureda, MD, Ph.D, Head of the Hematology Department at the Catalan Institute of Oncology, Barcelona, Spain - to discuss some of the exciting developments in the treatment of patients with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and Multiple Myeloma. <br/><br/>During our conversation we asked Dr Sureda about what she thinks about the exciting treatment options presented at the 59th Annual Meeting of the American Society of Hematology as well as the differences in how patients are being treated in the United States vs. Spain. <br/><br/>And we asked Dr Sureda about a particular study, the ECHELON-1, about the reason for the study, the study outcomes and what the results of this study mean for patients with advanced frontline Hodgkin lymphoma.

Changing the Treatment of Multiple Meyloma: A Conversation with Dr. Anna Sureda